Opinion|Videos|March 6, 2025

PEACE-3 Study Results: Safety

Author(s)Abhishek Tripathi, MD

An expert discusses the safety findings from the PEACE-3 study, highlighting the adverse events associated with the combination of enzalutamide and radium-223 in ARPI-naïve metastatic castration-resistant prostate cancer.

Episodes in this series

EP. 1 Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC

EP. 1 Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC

EP. 2 Therapeutic options for a patient with mCRPC after ADT + docetaxel

EP. 2 Therapeutic options for a patient with mCRPC after ADT + docetaxel

EP. 3 PEACE-3 study of enzalutamide + Ra-223 for ARPI-naïve mCRPC: Design and objectives

EP. 3 PEACE-3 study of enzalutamide + Ra-223 for ARPI-naïve mCRPC: Design and objectives

EP. 4 PEACE-3 Study Results: Study Population & Disposition

EP. 4 PEACE-3 Study Results: Study Population & Disposition

EP. 5 PEACE-3 Study Results: Efficacy

EP. 5 PEACE-3 Study Results: Efficacy

EP. 6 PEACE-3 Study Results: Safety

EP. 6 PEACE-3 Study Results: Safety

EP. 7 How would therapeutic options change if this patient was asymptomatic?

EP. 7 How would therapeutic options change if this patient was asymptomatic?

EP. 8 Protecting bone health for patients receiving Ra-223 + ARPI combination

EP. 8 Protecting bone health for patients receiving Ra-223 + ARPI combination

EP. 9 Ongoing studies of Ra-223–based combinations

EP. 9 Ongoing studies of Ra-223–based combinations

EP. 10 Ongoing studies of Ra- 223–based combinations

EP. 10 Ongoing studies of Ra- 223–based combinations

What about the safety findings?

Related Content

1 expert is featured in this series.

Systemic Therapy Selection and Guideline Based Sequencing in Progressive Small Bowel Neuroendocrine Tumor

ByChristopher Lieu, MD, FASCO

February 8th 2026

1 expert is featured in this series.

Clinical Framing and Prognostic Assessment in Progressive Small Bowel Neuroendocrine Tumors

ByChristopher Lieu, MD, FASCO

February 1st 2026

Experts featured in this series.

Future Directions in cGVHD Treatment

ByLeyla O. Shune, MD

January 26th 2026

Later-Line and Combination Therapies in cGVHD and Future Directions

ByZachariah DeFilipp, MD

January 23rd 2026

Experts featured in this series.

Sequencing in the cGVHD Treatment Paradigm

ByLeyla O. Shune, MD

January 19th 2026

Latest CME

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Manmeet Ahluwalia, MD, MBA

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

Shaina Rozell, MD, MPH; Seth A. Wander, MD, PhD

The 2nd Annual Hawaii Breast: A Multidisciplinary Case-Based Conference

The 2nd Annual Hawaii Breast: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD; Benjamin Falit, MD; Jami Fukui, MD; Laura Huppert, MD; Sara A. Hurvitz, MD, FACP; Jodi Kagihara, MD; Irene Kang, MD; William Loui, MD, FACP; Ashley Marumoto, MD; Rebecca Shatsky, MD; Naoko Takebe, MD, PhD; Melinda Telli, MD, FASCO; Rachel Thelen, FNP-C, AOCNP; Teruo Yamauchi, MD, MS

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

43rd Annual Miami Breast Cancer Conference®

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Munaf Alkadimi, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO